PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitors' Response and Survival in Advanced Melanoma Patients in Brazil

Autor(es)

Sorroche, Bruna Pereira ; Teixeira, Renan de Jesus ; Pereira, Caio Augusto Dantas ; Santana, Iara Viana Vidigal ; Vujanovic, Lazar ; Vazquez, Vinicius de Lima ; Arantes, Lidia Maria Rebolho Batista

• Tipo de documento: Artigo Científico
• Fonte: DIAGNOSTICS; v. 13, n. 6, p. 11-pg., 2023-03-01.

Resumo

Immune checkpoint blockade (ICB) agents are prominent immunotherapies for the treatment of advanced melanoma. However, they fail to promote any durable clinical benefit in a large cohort of patients. This study assessed clinical and molecular predictors of ICB response and survival in advanced melanoma. A retrospective analysis was performed on 210 patients treated with PD-1 or CTLA-4 inhibitors at Barretos Cancer Hospital, Brazil. PD-L1 expression was assessed by immunohistochemistry using formalin-fixed paraffin-embedded tumor tissues collected prior to ICB therapy. Patients were divided into responders (complete and partial response and stable disease for more than 6 months) and non-responders (stable disease for less than 6 months and progressive disease). Among them, about 82% underwent anti-PD-1 immunotherapy, and 60.5% progressed after the ICB treatment. Patients that received ICB as first-line therapy showed higher response rates than previously treated patients. Higher response rates were further associated with superficial spreading melanomas and positive PD-L1 expression (>1%). Likewise, PD-L1 positive expression and BRAF V600 mutations were associated with a higher overall survival after ICB therapy. Since ICBs are expensive therapies, evaluation of PD-L1 tumor expression in melanoma patients should be routinely assessed to select patients that are most likely to respond. (AU)

• Processo FAPESP: 19/03570-9 - Inibidores do checkpoint imunológico: desfecho clínico e biomarcadores para predição de resposta em pacientes com Melanoma
• Beneficiário: Bruna Pereira Sorroche
• Modalidade de apoio: Bolsas no Brasil - Doutorado
• Processo FAPESP: 21/04100-6 - Inibidores de checkpoint imunológico: imunofenotipagem e desfecho clínico para predição de resposta no Hospital de Câncer de Barretos
• Beneficiário: Lidia Maria Rebolho Batista Arantes
• Modalidade de apoio: Bolsas no Brasil - Jovens Pesquisadores
• Processo FAPESP: 19/07111-9 - Inibidores de checkpoint imunológico: imunofenotipagem e desfecho clínico para predição de resposta no Hospital de Câncer de Barretos
• Beneficiário: Lidia Maria Rebolho Batista Arantes
• Modalidade de apoio: Auxílio à Pesquisa - Jovens Pesquisadores
• Processo FAPESP: 21/10922-9 - Analisando o perfil epigenético das células T CD8+ infiltrantes de tumor para superar o meio imunossupressor dos nichos hipóxicos tumorais
• Beneficiário: Bruna Pereira Sorroche
• Modalidade de apoio: Bolsas no Exterior - Estágio de Pesquisa - Doutorado